Banner Sun Health Research Institute (BSHRI), a part of nonprofit Banner Health, has announced the launch a new clinical trial for patients with mild to moderate Alzheimer's disease (AD) in United States. This study, titled "Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the cognitive function of mild to moderate Alzheimer patients," utilizes NeuroAD technology, a noninvasive approach to reduce memory decline as a result of AD.

The NeuroAD system by Neuronix is an innovative, non-pharmaceutical treatment alternative for the treatment of mild to moderate Alzheimer's disease. This cutting-edge study involves non-invasive, Transcranial Magnetic Stimulation (TMS) and cognitive exercises in the NeuroAD chair. The device sends magnetic waves into the brain. This stimulation combined with cognitive exercises is expected to result in a measurable cognitive improvement after just a few weeks of treatment.

"Preliminary studies demonstrate that this is a safe and potentially effective treatment for Alzheimer's disease," said Marwan Sabbagh, MD, the director at Banner Sun Health Research Institute and Principal Investigator for the study at the facility. "There hasn't been a new treatment for Alzheimer's in a long time, which makes this particularly exciting."

The study being conducted at Banner Sun Health Research Institute, located at 10515 W. Santa Fe Dr. in Sun City, is looking for patients with mild to moderate AD to participate. After screening to determine eligibility, participants would come in for the NeuroAD treatment one hour a day, five days a week for six weeks.

Banner Sun Health Research Institute, part of nonprofit Banner Health, has been a leader nationally and internationally in the effort to find answers to disorders of aging including Alzheimer's and Parkinson's disease. The institute, together with its Arizona Alzheimer's Consortium partners, has been designated by the National Institutes of Health as one of just 29 Alzheimer's disease Centers in the nation.